TFIIIC110 Antibody (2395C2a): sc-81406

TFIIIC110 Antibody (2395C2a) is a mouse monoclonal IgG1 antibody that detects TFIIIC110 protein of human origin by western blotting (WB) and immunoprecipitation (IP). Anti-TFIIIC110 antibody (2395C2a) is available as a non-conjugated format, providing researchers with a reliable tool for studying this critical protein. TFIIIC110 plays a vital role in the transcription of genes by RNA polymerase III, which is responsible for synthesizing essential RNA molecules such as tRNA and 5S rRNA. This function is particularly important because RNA polymerase III activity regulation is crucial for cellular growth and proliferation, especially in cancerous cells where rapid division is necessary. TFIIIC110 is part of the TFIIIC2 transcription factor complex, which is composed of multiple subunits, including TFIIIC220, TFIIIC102, TFIIIC90, and TFIIIC63. This complex is essential for recruiting RNA polymerase III and the TFIIIB complex to promoter elements, thereby facilitating the transcription of genes that are often overexpressed in transformed cells and tumors. Notably, TFIIIC110 and associated subunits are frequently upregulated in various malignancies, including ovarian carcinomas, highlighting potential as a biomarker for cancer progression and a target for therapeutic intervention. Understanding TFIIIC110 dynamics and interactions within the transcription machinery can provide insights into the mechanisms of tumorigenesis and the development of novel cancer treatments.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

TFIIIC110 Antibody (2395C2a) References:

1. The TFIIIC90 subunit of TFIIIC interacts with multiple components of the RNA polymerase III machinery and contains a histone-specific acetyltransferase activity.  |  Hsieh, YJ., et al. 1999. Mol Cell Biol. 19: 7697-704. PMID: 10523658
2. Interactions between the tetratricopeptide repeat-containing transcription factor TFIIIC131 and its ligand, TFIIIB70. Evidence for a conformational change in the complex.  |  Moir, RD., et al. 2000. J Biol Chem. 275: 26591-8. PMID: 10859316
3. Alternatively spliced hBRF variants function at different RNA polymerase III promoters.  |  McCulloch, V., et al. 2000. EMBO J. 19: 4134-43. PMID: 10921893
4. Different human TFIIIB activities direct RNA polymerase III transcription from TATA-containing and TATA-less promoters.  |  Schramm, L., et al. 2000. Genes Dev. 14: 2650-63. PMID: 11040218
5. RNA polymerase III transcription factor TFIIIC2 is overexpressed in ovarian tumors.  |  Winter, AG., et al. 2000. Proc Natl Acad Sci U S A. 97: 12619-24. PMID: 11058163
6. Retinoblastoma protein disrupts interactions required for RNA polymerase III transcription.  |  Sutcliffe, JE., et al. 2000. Mol Cell Biol. 20: 9192-202. PMID: 11094071
7. RNA polymerase III transcription: its control by tumor suppressors and its deregulation by transforming agents.  |  Brown, TR., et al. 2000. Gene Expr. 9: 15-28. PMID: 11097422
8. Nuclear factor 1 (NF1) affects accurate termination and multiple-round transcription by human RNA polymerase III.  |  Wang, Z., et al. 2000. EMBO J. 19: 6823-32. PMID: 11118217
9. A test of the model that RNA polymerase III transcription is regulated by selective induction of the 110 kDa subunit of TFIIIC.  |  Innes, F., et al. 2006. Nucleic Acids Res. 34: 3399-407. PMID: 16822860
10. Leishmania-induced repression of selected non-coding RNA genes containing B-box element at their promoters in alternatively polarized M2 macrophages.  |  Farrow, AL., et al. 2011. Mol Cell Biochem. 350: 47-57. PMID: 21165676
11. Activation of mouse genes in transformed cells.  |  Scott, MR., et al. 1983. Cell. 34: 557-67. PMID: 6311432
12. Expression of neural BC1 RNA: induction in murine tumours.  |  Chen, W., et al. 1997. Eur J Cancer. 33: 288-92. PMID: 9135502

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-TFIIIC110 Antibody (2395C2a) has 9 citations in a variety of scientific publications.

Primary antibodies like Anti-TFIIIC110 Antibody (2395C2a) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

TFIIIC110 Antibody (2395C2a) Specifications

Alternate Product Name: TFIIIC110

Product Clone Name: 2395C2a

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁

Amino Acids:

Epitope Target: TFIIIC110

Epitope Species: human

Product Reactivity/Detection: TFIIIC110

Species Reactivity/Detection: human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP

Vialing Information: Each vial contains 100 µg IgG₁ in 1.0 ml of PBS with < 0.1% sodium azide and 1.0% stabilizer protein

Research Citations: 9 citations in various scientific publications

Available Conjugates/Forms for TFIIIC110 Antibody (2395C2a): N/A